Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Cash from Investing Activities: 2022-2025

Historic Cash from Investing Activities for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Sep 2025 value amounting to -$2.6 million.

  • Corvus Pharmaceuticals' Cash from Investing Activities rose 32.70% to -$2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$24.8 million, marking a year-over-year decrease of 4.38%. This contributed to the annual value of -$27.5 million for FY2024, which is 276.85% down from last year.
  • Latest data reveals that Corvus Pharmaceuticals reported Cash from Investing Activities of -$2.6 million as of Q3 2025, which was up 87.10% from -$20.3 million recorded in Q2 2025.
  • In the past 5 years, Corvus Pharmaceuticals' Cash from Investing Activities registered a high of $17.5 million during Q3 2023, and its lowest value of -$25.6 million during Q1 2022.
  • In the last 3 years, Corvus Pharmaceuticals' Cash from Investing Activities had a median value of -$2.6 million in 2025 and averaged -$2.8 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first crashed by 308.11% in 2024, then surged by 60,714.29% in 2025.
  • Corvus Pharmaceuticals' Cash from Investing Activities (Quarterly) stood at -$3.9 million in 2022, then soared by 40.29% to -$2.3 million in 2023, then slumped by 162.42% to -$6.1 million in 2024, then soared by 32.70% to -$2.6 million in 2025.
  • Its last three reported values are -$2.6 million in Q3 2025, -$20.3 million for Q2 2025, and $4.2 million during Q1 2025.